EISAI INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

Phase 3

Completed

Conditions: Insomnia Disorder

Interventions: Drug: lemborexant
Drug: Placebo

First Posted Date: 2016-11-02

Last Posted Date: 2020-02-06

Lead Sponsor: Eisai Inc.

Target Recruit Count: 971

Registration Number: NCT02952820

Locations: 🇵🇱
Facility # 2, Warszawa, Poland
🇯🇵
Eisai Trial Site 3, Yokohama, Kanagawa, Japan
🇯🇵
Eisai Trial Site 2, Yokohama, Kanagawa, Japan

and more 8 locations

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Phase 2

Completed

Conditions: Non Clear Cell Renal Cell Carcinoma (nccRCC)

Interventions: Drug: lenvatinib
Drug: everolimus

First Posted Date: 2016-09-27

Last Posted Date: 2023-01-17

Lead Sponsor: Eisai Inc.

Target Recruit Count: 41

Registration Number: NCT02915783

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 5 locations

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: perampanel

First Posted Date: 2016-09-26

Last Posted Date: 2024-03-15

Lead Sponsor: Eisai Inc.

Target Recruit Count: 26

Registration Number: NCT02914314

Locations: 🇺🇸
Axcess Medical Research, Loxahatchee Groves, Florida, United States
🇺🇸
Pediatric Epilepsy And Neurology Specialists, Tampa, Florida, United States
🇺🇸
NW FL Clinical Research Group, LL-ClinEdge- PPDS, Gulf Breeze, Florida, United States

and more 15 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: E2027
Drug: E2027 matched placebo

First Posted Date: 2016-08-19

Last Posted Date: 2018-09-07

Lead Sponsor: Eisai Inc.

Target Recruit Count: 74

Registration Number: NCT02873156

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Phase 1

Completed

Conditions: Early Alzheimer's Disease

Interventions: Drug: E2609

First Posted Date: 2016-08-08

Last Posted Date: 2017-06-08

Lead Sponsor: Eisai Inc.

Target Recruit Count: 32

Registration Number: NCT02859207

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Phase 3

Completed

Conditions: Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Interventions: Drug: Perampanel

First Posted Date: 2016-07-29

Last Posted Date: 2022-10-28

Lead Sponsor: Eisai Inc.

Target Recruit Count: 180

Registration Number: NCT02849626

Locations: 🇯🇵
Eisai Trial Site #1, Yokohama-shi, Japan
🇰🇷
Facility #3, Seoul, Korea, Republic of
🇪🇸
Facility #2, Barcelona, Spain

and more 1 locations

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Phase 3

Terminated

Conditions: Lennox-Gastaut Syndrome (LGS)

Interventions: Drug: Placebo
Drug: Perampanel

First Posted Date: 2016-07-15

Last Posted Date: 2022-03-09

Lead Sponsor: Eisai Inc.

Target Recruit Count: 101

Registration Number: NCT02834793

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇮🇳
Synexus Affiliate - Mallikatta Neuro Center, Mangalore, Karnataka, India
🇦🇺
Royal Brisbane & Women's Hospital, Brisbane, Australia

and more 62 locations

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Lenvatinib
Drug: Sunitinib
Drug: Everolimus
Drug: Pembrolizumab

First Posted Date: 2016-06-23

Last Posted Date: 2024-11-01

Lead Sponsor: Eisai Inc.

Target Recruit Count: 1069

Registration Number: NCT02811861

Locations: 🇮🇱
Chaim Sheba Medical Center, Ramat-Gan, Israel
🇯🇵
Facility #2, Tokyo, Japan
🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States

and more 159 locations

Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Avatrombopag
Drug: Fluconazole
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2016-06-22

Last Posted Date: 2017-03-09

Lead Sponsor: Eisai Inc.

Target Recruit Count: 48

Registration Number: NCT02809768

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Lenvatinib

First Posted Date: 2016-06-08

Last Posted Date: 2019-03-14

Lead Sponsor: Eisai Inc.

Target Recruit Count: 60

Registration Number: NCT02792829

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy